AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
TransCode Therapeutics, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00ZGYHVW8
1.77▲ 0.05 (3.21%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
1.72
Day's Range
1.65 – 1.84
52-Week Range
1.52 – 13.96
Volume
32.5K
Avg Volume
46.1K
Share Statistics
Shares Outstanding
Employees
12
Exchange
XNAS
Listed
2021-07-09
Share count as of August 10, 2026

TransCode Therapeutics, Inc. Common Stock (RNAZ) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about TransCode Therapeutics, Inc. Common Stock (RNAZ)
What is TransCode Therapeutics, Inc. Common Stock's Market Cap?
TransCode Therapeutics, Inc. Common Stock's Market Cap is $30.0M, based on as-reported figures from SEC (XBRL) filings.
What is TransCode Therapeutics, Inc. Common Stock's Enterprise Value?
TransCode Therapeutics, Inc. Common Stock's Enterprise Value is $21.6M, based on as-reported figures from SEC (XBRL) filings.
What is TransCode Therapeutics, Inc. Common Stock's EV / EBITDA?
TransCode Therapeutics, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is TransCode Therapeutics, Inc. Common Stock's Net Income (TTM)?
TransCode Therapeutics, Inc. Common Stock's Net Income (TTM) is -$42.8M, based on as-reported figures from SEC (XBRL) filings.
What is TransCode Therapeutics, Inc. Common Stock's EBITDA?
TransCode Therapeutics, Inc. Common Stock's EBITDA is -$45.0M, based on as-reported figures from SEC (XBRL) filings.
What is TransCode Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
TransCode Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -2.53, based on as-reported figures from SEC (XBRL) filings.
What is TransCode Therapeutics, Inc. Common Stock's Net Debt?
TransCode Therapeutics, Inc. Common Stock's Net Debt is -$8.4M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · RNAZAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses
Research and development
General and administrative
SEPA financing issuance costs——
Total operating expenses
Operating loss
Other income (expense)
Change in fair value of warrant liabilities
Change in fair value of contingent consideration——
PIPE warrant Issuance Costs——
Grant income
Currency exchange loss
Interest income
Interest expense—
Total other income (expense)
Loss before income tax provision——
Deferred income tax provision——
Net loss——
Net loss attributable to common stockholders
Net loss attributable to common stockholders, diluted——
Net loss per share, Basic (in dollars per share)—
Net loss per share, Diluted (in dollars per share)—